From: Emerging strategies and applications of pharmacogenomics
Therapeutic | Indication | Phenotype investigated | Gene/genomic relationship | References |
---|---|---|---|---|
Carbamazepine | Seizures | Stevens-Johnson syndrome | HLA-B* 1502 | [56] |
Metoprolol | Hypertension | Blood pressure lowering | Beta-1 adrenergic receptor | [57] |
Abacavir | HIV | Hypersensitivity | HLA-B* 5701 | |
 |  |  | HLA-DR7 |  |
 |  |  | HLA-DQ3 |  |
Raloxifene | Osteoporosis | Bone mineral density | Vitamin D receptor | [60] |
Tolcapone | Parkinson's disease | Elevated liver transaminase levels | UDP-glucuronosyltransferase 1A | [61] |
Azathiopurine, mercaptopurine, thioguanine | Childhood leukaemia | Drug exposure | Thiopurine S-methyltransferase-inactivating mutation | [62] |
Zileuton | Asthma | FEV1 response | 5-lipoxygenase promoter variant | [63] |
Fluvoxamine | Depression | Drug response based on Hamilton Depression Rating Scale | Serotonin transporter | [64] |
Sertraline | Depression | Time to therapeutic response | Serotonin transporter | [65] |
Enalaprilat | Hypertension | Blood pressure lowering | ACE Ins/Del | [66] |